Yahoo
NSE - Delayed Quote INR

Rubicon Research Limited (RUBICON.NS)

1,610.50 +51.20 (+3.28%)
At close: October 30 at 3:30:02 PM GMT+5:30
Chart Range Bar
Loading chart for RUBICON.NS
  • Previous Close 1,559.30
  • Open 1,545.60
  • Bid --
  • Ask --
  • Day's Range 1,537.90 - 1,628.80
  • 52 Week Range 607.15 - 1,899.00
  • Volume 197,691
  • Avg. Volume 307,177
  • Market Cap (intraday) 266.601B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 92.77
  • EPS (TTM) 17.36
  • Earnings Date --
  • Forward Dividend & Yield 1.50 (0.09%)
  • Ex-Dividend Date Aug 7, 2026
  • 1y Target Est 1,897.50

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant. Its primary proprietary technologies for drug delivery comprising RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption, as well as RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies. The company was incorporated in 1999 and is headquartered in Mumbai, India.

www.rubicon.co.in

1,290

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

RUBICON.NS
136.81%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

RUBICON.NS
164.36%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

RUBICON.NS
159.76%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

RUBICON.NS
159.76%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY26
Revenue 5.14B
Earnings 767.85M
Profit Margin 14.94%

Q1

FY26

Q2

FY26

Q3

FY26

Q4

FY26

0
1B
2B
3B
4B
5B
0.0%
5.0%
10.0%
15.0%

Analyst Insights

View More

Analyst Price Targets

1,880.00
1,897.50 Average
1,610.50 Current
1,915.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.89%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    19.36B

  • Net Income Avi to Common (ttm)

    2.88B

  • Diluted EPS (ttm)

    17.36

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.33B

  • Total Debt/Equity (mrq)

    24.13%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: